down she goes, page-69

So 7-10% market share with a small discount on the brand name isn't so bad after all....

I wasn’t aware, but after doing some research it seems that when Reddy’s launch first to market generic's, they virtually match the price to the brand name- only small discounts are initially offered… hence the slow uptake, and the market share going to the AG- I presume that's what Serendipity is getting at?

Classic example is when Reddy's launched their first to market generic Imitrex- also produced GSK. GSK sold 8 doses of Imtrex for $240 , when Reddys first launched their generic version(sumatriptan) 8 doses sold for $220....

This supports what Riverboat posted up in another thread regarding arixtra vs fonda pricing- http://www.mohawkmedical.com/store_search?model=&field_search_name_value=fondaparinux&field_search_dosage_form_descrip_value=&field_dosage_strength_value=


@ 2.5mg arixtra is selling for $116.51, with fonda selling for 114.90